Cme Group INC Form 4 insider transactions

Julie Winkler, CME Group's Sr MD Chief Commercial Officer, reported the acquisition and disposition of Common Stock Class A shares related to restricted stock vesting and tax obligations.

CME Group's Chief Transformation Officer, Ken Vroman, reported the acquisition and disposition of Common Stock Class A shares related to restricted stock vesting and tax obligations.

Jonathan L. Marcus, CME Group's Sr MD General Counsel, reported acquisitions, sales, and tax-related dispositions of company stock.

CME Group's Chief Operating Officer, Suzanne Sprague, reported the acquisition of 3,044 shares and disposition of 964 shares for tax obligations related to restricted stock vesting.

CME Group's President and CFO, Lynne Fitzpatrick, reported routine acquisitions and dispositions of common stock tied to restricted stock vesting and tax obligations.

Jack J. Tobin, CME Group's MD Chief Accounting Officer, reported the vesting of restricted stock and subsequent share dispositions to cover tax obligations.

Michael G. Dennis, CME Group's Global Head of Fixed Income, reported a planned acquisition of 2,608 shares and a subsequent disposition of 289 shares for tax obligations in September 2025.

CME Group Senior Managing Director Timothy McCourt reported stock acquisitions and dispositions related to restricted stock vesting and tax obligations.

CME Group Senior Managing Director Derek Sammann reported recent acquisitions and tax-related dispositions of company stock.

CME Group's Chairman and CEO, Terrence A. Duffy, acquired 23,180 shares of Common Stock Class A at a price of $258.83 per share.

CME Group's Sr MD & Chief HR Officer, Hilda Harris Piell, reported recent stock transactions involving the vesting of restricted stock and subsequent tax withholdings, resulting in a net increase in her beneficial ownership.

CME Group's Chief Information Officer, Sunil Cutinho, sold 11,896 shares of Class A common stock in pre-planned transactions.

CME Group Inc. Director Patrick W. Maloney has acquired 532 shares of Common Stock Class A at a price of $273.03 per share, increasing his direct beneficial ownership to 4,098 shares.

CME Group Inc. Director Harold Eugene Ford Jr. acquired 532 shares of Common Stock Class A at a price of $273.03 per share on June 25, 2025, as part of the company's Director Stock Plan.

CME Group Director Elizabeth A. Cook acquired 532 shares of Common Stock Class A at $273.03 per share on June 25, 2025, increasing her beneficial ownership.

CME Group Inc. Director Timothy S. Bitsberger acquired 532 shares of Common Stock Class A at a price of $273.03 per share, increasing his total beneficial ownership to 11,121 shares, as part of the company's Director Stock Plan.

CME Group Inc. Director Rahael Seifu has reported the future acquisition of 532 shares of Common Stock Class A, valued at $273.03 per share, effective June 25, 2025, as part of the company's Director Stock Plan.

CME Group Inc. Director Patrick J. Mulchrone has filed a Form 4 indicating a future acquisition of 532 shares of Class A Common Stock on June 25, 2025, as part of the company's Director Stock Plan.

Phyllis M. Lockett, a Director at CME Group Inc., increased her stake in the company by acquiring 532 shares of common stock at a price of $273.03 per share.

CME Group Inc. Director Deborah J. Lucas acquired 532 shares of Common Stock Class A at a price of $273.03 per share on June 25, 2025, increasing her total beneficial ownership to 3,888 shares.

CME Group Inc. Director Bryan T. Durkin acquired 532 shares of Common Stock Class A at a price of $273.03 per share, increasing his beneficial ownership to 47,207 shares, as part of the company's Director Stock Plan.

CME Group Inc. Director Daniel G. Kaye acquired 532 shares of Common Stock Class A on June 25, 2025, as part of the company's Director Stock Plan, increasing his total beneficial ownership to 4,200 shares.

CME Group Inc. Director Charles P. Carey was granted 879 shares of Class A Common Stock as part of the company's Director Stock Plan, increasing his beneficial ownership.

CME Group Inc. Director William W. Hobert reported the acquisition of 879 shares of Class A Common Stock at a price of $273.03 per share, granted under the company's Director Stock Plan.

CME Group Inc. Director Martin J. Gepsman acquired 532 shares of Common Stock Class A at $273.03 per share, increasing his beneficial ownership to 25,299 shares, as reported in a recent SEC Form 4 filing.

CME Group Inc. Director Howard J. Siegel acquired 879 shares of Common Stock Class A on June 25, 2025, through the company's Director Stock Plan.

CME Group Inc. Director Dennis Suskind acquired 532 shares of Common Stock Class A at $273.03 per share on June 25, 2025, as part of the company's Director Stock Plan.

CME Group Inc. Director Kathryn Benesh acquired 532 shares of common stock at $273.03 per share on June 25, 2025, as part of the company's Director Stock Plan.

CME Group Inc. Director Robert J. Tierney Jr. acquired 532 shares of common stock at $273.03 per share, increasing his direct beneficial ownership to 13,700 shares, as part of the company's Director Stock Plan.

CME Group Director William R. Shepard has reported the acquisition of additional Class A common stock through a stock plan grant and dividend reinvestment, increasing his beneficial ownership.